ENDRA Life Sciences Inc
NASDAQ:NDRA
ENDRA Life Sciences Inc
Total Receivables
ENDRA Life Sciences Inc
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ENDRA Life Sciences Inc
NASDAQ:NDRA
|
Total Receivables
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Total Receivables
$2.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
14%
|
CAGR 10-Years
9%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Total Receivables
$912.1m
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
Stryker Corp
NYSE:SYK
|
Total Receivables
$4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
9%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Total Receivables
$7.9B
|
CAGR 3-Years
8%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Total Receivables
$1.5B
|
CAGR 3-Years
17%
|
CAGR 5-Years
19%
|
CAGR 10-Years
15%
|
|
ENDRA Life Sciences Inc
Glance View
ENDRA Life Sciences, Inc. develops medical imaging technology. The company is headquartered in Ann Arbor, Michigan and currently employs 22 full-time employees. The company went IPO on 2017-06-28. The firm has developed a technology platform, Thermo Acoustic Enhanced Ultrasound (TAEUS), which is intended to enhance the capability of clinical ultrasound technology and support the diagnosis and treatment of various other medical conditions. Its TAEUS technology platform application focuses on quantifying fat in the liver and stage progression of non-alcoholic fatty liver disease (NAFLD), which untreated, can progress to Non-alcoholic Steatohepatitis (NASH), fibrosis, cirrhosis, and liver cancer. The firm's TAEUS platform has various clinical applications, such as tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.
